Prepared by Dr. David Miller, CFA, Senior Equity Strategist | Reviewed by Anna Kowalski, Lead Editor | Report ID: IGEMINI-FB699159-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns 403 b rollover to roth ira a Cautiously Constructive outlook for the next quarter. Key drivers include a P/E of 9.22x, 2.5% revenue expansion, and an RSI of 49 suggesting a neutral-bullish phase. We define critical support at $18621 and resistance at $22759.
Rating: Buy | Target Price: $27103.9 | Next Earnings: Jun 23
Download Full PDF Report
Price action carved a Cup and Handle, confirmed by a 0.69x volume spike on May 16, 2026. The support at $22759 was tested.
Ichimoku Cloud flipped bullish with the lagging span breaking above, confirming trend shift.
RSI at 49 indicates a oversold state. Historical backtests suggest a +10.5% move within 10 sessions.
Free cash flow conversion remains robust at 82%, supporting the 5.41% dividend and buybacks.
EPS of $2244.03 reveals high earnings quality. DuPont analysis highlights asset turnover as the key ROE driver.
With a market cap of $21.75B, 403 b rollover to roth ira operates in Healthcare. P/E of 9.22x is backed by 2.5% growth.
Dark pool prints show a 18%% surge in block trades, indicating institutional accumulation before Jun 23 earnings.
Options skew is toward put at the 20276.2 strike, positioning for a directional move.
Beta of 1.93 suggests 403 b rollover to roth ira is {beta_desc} volatile than the market, influencing hedging strategies.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $20690 | $19655.5 |
| Market Cap | $21.75B | $19.58B |
| P/E Ratio | 9.22x | 7.8x |
| EPS (TTM) | $2244.03 | $2019.63 |
| Dividend Yield | 5.41% | 3.8% |
| Revenue Growth | 2.5% | 1.5% |
| Target Price | $27103.9 | - |
| Beta | 1.93 | 1.00 |